StreetInsider.com News Articles

BioCryst Pharma (BCRX) Reiterated at Market Outperform by Citizens on Orladeyo Potential

Fri, 17 Jul 2026 05:10:12 -0400

Citizens analyst Jonathan Wolleben reiterated a Market Outperform rating and $28.00 price target on BioCryst Pharma (NASDAQ: BCRX).

The analyst commented, "We reiterate our Market Outperform rating and $28 risk-adjusted, DCF-derived price target on BioCryst Pharmaceuticals. For 2Q26, we model $160M in Orladeyo revenues (up 8% from 1Q), in line with consensus at $161M. As a reminder, BCRX has guided to 2026 Orladeyo revenue of $625-$645M, while we think Orladeyo can slightly outperform (Citizens estimate of $648M vs. consensus of $642M)."

For an analyst ratings summary and ratings history on BioCryst Pharma click here. For more ratings news on BioCryst Pharma

BioCryst names David Jenkins as chief scientific officer

Wed, 15 Jul 2026 07:01:21 -0400

BioCryst Pharmaceuticals (NASDAQ: BCRX) has appointed David W. Jenkins as chief scientific officer, a newly created position, effective immediately, according to a press release from the Research Triangle Park, N.C.-based company.

Jenkins will report to Sandeep Menon, chief research and development officer, and will be based in BioCryst's Boston office. His role will focus on building a research team centered on external partnerships and innovation to advance rare disease therapies.

Jenkins brings more than 20 years of biopharmaceutical experience. He most recently served as senior vice president and head of research and external innovation at Ipsen, where he oversaw preclinical drug discovery

BioCryst names David Jenkins as chief scientific officer

Wed, 15 Jul 2026 07:01:21 -0400

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Wed, 15 Jul 2026 07:00:00 -0400

RESEARCH TRIANGLE PARK, N.C., July 15, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced the appointment of David W. Jenkins, MA, PhD, to the newly created position of Chief Scientific Officer, effective immediately, reporting to Dr. Sandeep Menon, Chief Research and Development Officer. In this role, Dr. Jenkins will build and lead an efficient research team focused on leveraging external innovation, capabilities and partnerships to accelerate the delivery of transformative rare disease therapies to patients. He will be based in the Company’s Boston office.

Dr. Jenkins has spent over 20

BioCryst Appoints David W. Jenkins as Chief Scientific Officer

Wed, 15 Jul 2026 07:00:00 -0400

Dr. Jenkins has spent over 20

JPMorgan Resumes BioCryst Pharma (BCRX) at Neutral

Mon, 13 Jul 2026 03:15:04 -0400

JPMorgan analyst Jessica Fye resumes coverage on BioCryst Pharma (NASDAQ: BCRX) with a Neutral rating and a price target of $12.00.

The analyst comments: “We are moving to a Neutral rating and establishing a $12 Dec 2027 price target for BCRX. We see BCRX shifting to a biz-dev driven model enabled by the acquisition of Astria, which brought in navenibart for HAE prophylaxis, a potential Q3M or even Q6M injectable product. We see navenibart shoring up the longer-term top-line outlook with a competitive agent in the injectable segment launching around the time Orladeyo may begin to peak out. While we see

JPMorgan Resumes BioCryst Pharma (BCRX) at Neutral

Mon, 13 Jul 2026 03:15:04 -0400

JPMorgan analyst Jessica Fye resumes coverage on BioCryst Pharma (NASDAQ: BCRX) with a Neutral rating and a price target of $12.00.

BioCryst Pharma (BCRX) PT Raised to $14 at RBC Capital

Tue, 07 Jul 2026 07:55:06 -0400

RBC Capital analyst Brian Abraham raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $14.00 (from $13.00) while maintaining a Outperform rating.

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:00:00 -0400

RESEARCH TRIANGLE PARK, N.C., July 02, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) today announced that the compensation committee of BioCryst’s board of directors granted nine newly-hired employees stock options to purchase an aggregate of 33,950 shares, and restricted stock units (RSUs) covering an aggregate of 91,750 shares, of BioCryst common stock. The options and RSUs were granted as of July 1, 2026, as inducements material to each employee entering into employment with BioCryst. The options and RSUs were granted in accordance with Nasdaq Listing Rule 5635(c)(4).

The options

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:00:00 -0400

The options

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:00:00 -0400

The options

BioCryst Reports Inducement Grants Under Nasdaq Listing Rule 5635(c)(4)

Thu, 02 Jul 2026 07:00:00 -0400

The options

BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies

Tue, 30 Jun 2026 04:42:55 -0400

Jefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $17.00 (from $14.00) while maintaining a Buy rating.

The analyst comments "BCRX is transitioning to a more capital efficient R&D model by prioritizing external innovation vs internal discovery, which we view as a (+)ve. Strong balance sheet, sustained double-digit% rev growth expectations, and tightly controlled expense growth underpins the strategic shift. We updated our model accounting for rev OpEX non-GAAP guidance. Also, navenibart ph.III completed enrollment w/ topline in 3Q27, and Netherton ph.I data remains on-track for YE26."

BioCryst Pharma (BCRX) PT Raised to $17 at Jefferies

Tue, 30 Jun 2026 04:42:55 -0400

Jefferies analyst Maury Raycroft raised the price target on BioCryst Pharma (NASDAQ: BCRX) to $17.00 (from $14.00) while maintaining a Buy rating.

Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25

Mon, 29 Jun 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260629/26701962.html

Form 8-K BIOCRYST PHARMACEUTICALS For: Jun 25

Mon, 29 Jun 2026 07:07:00 -0400

si-local-file:///var/storage/secattach/20260629/26701962.html

BioCryst to close Birmingham lab and shift to external R&D model

Mon, 29 Jun 2026 07:00:40 -0400

BioCryst Pharmaceuticals (Nasdaq: BCRX) said it will shut down its internal discovery programs and close its Discovery Center of Excellence in Birmingham, Alabama by the end of 2026, pivoting to an externally focused research strategy for its rare disease pipeline.

The company said the decision followed a strategic review of its research capabilities and priorities. Going forward, BioCryst plans to identify pipeline candidates through external partnerships and licensing rather than internal discovery.

As a result of the restructuring, BioCryst lowered its full-year 2026 non-GAAP operating expense guidance to $420–$440 million, down from a prior range of $450–$470 million. The company reaffirmed its

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Mon, 29 Jun 2026 07:00:00 -0400

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—

—Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE study to date—

—Resolves previously disclosed manufacturing delay of ORLADEYO^® (berotralstat) oral pellets; product to be available in early August—

—Improves 2026 non-GAAP operating expense guidance from $450-$470 million to $420-$440 million and reaffirms revenue guidance—

RESEARCH TRIANGLE PARK, N.C., June 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced that, as part

BioCryst Sharpens Scientific Focus on External Innovation with Wind Down of Internal Discovery Programs and Closure of Birmingham Research Facility

Mon, 29 Jun 2026 07:00:00 -0400

—Advances strategic shift toward a disciplined research model prioritizing external innovation to accelerate rare disease pipeline growth—

—Completes enrollment in Phase 3 ALPHA-ORBIT for navenibart, largest pivotal HAE study to date—

—Resolves previously disclosed manufacturing delay of ORLADEYO^® (berotralstat) oral pellets; product to be available in early August—

—Improves 2026 non-GAAP operating expense guidance from $450-$470 million to $420-$440 million and reaffirms revenue guidance—

RESEARCH TRIANGLE PARK, N.C., June 29, 2026 (GLOBE NEWSWIRE) -- BioCryst Pharmaceuticals, Inc. (Nasdaq: BCRX) (“BioCryst” or the “Company”) today announced that, as part

Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Milne Jill C.

Mon, 15 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26647912.html

Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Milne Jill C.

Mon, 15 Jun 2026 16:32:00 -0400

si-local-file:///var/storage/secattach/20260615/26647912.html

Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Galson Steven K

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647879.html

Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: Galson Steven K

Mon, 15 Jun 2026 16:31:00 -0400

si-local-file:///var/storage/secattach/20260615/26647879.html

Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: LEVIN ALAN G

Mon, 15 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260615/26647807.html

Form 4 BIOCRYST PHARMACEUTICALS For: Jun 11 Filed by: LEVIN ALAN G

Mon, 15 Jun 2026 16:29:00 -0400

si-local-file:///var/storage/secattach/20260615/26647807.html